Pharmaceutical Executive, Jun 1, 2008 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jun 1, 2008
Features
Stealth Pharmas
By Bill Trombetta
Second annual Not Big Pharma audit gives equal time to the little guys. Who's got the Midas touch?
Blueprint for Excellence
By John Moran , Chris Nickum
In a time of slow growth, true innovators forge new relationships with core customers
Being Bob: Q&A with Robert Essner
By Patrick Clinton
An industry legend weighs in on leadership, research, and sales models. Q&A with outgoing Wyeth Chairman Bob Essner
45 Under 45:The Change Generation
By Walter Armstrong , Joanna Breitstein
In our first ever Emerging Leadership Awards, we profile 45 talented young professionals who will lead pharma into the next generation
Columns
Mightier Than the Sword
By David Kweskin , Wes Michael
When it comes to marketing, every syllable speaks volumes
Doctor's Orders
By Sara Donnelly, Associate Editor
Dr. Michael Kessler and Mark Vitello of MD Mindset have the cure for the common sales pitch? Look at the transaction from the customer's perspective
The Web Video (R)evolution
By Matt DeLoca
Pharma is taking note of online video's power to affect B2B communications
Washington Report
Candidates Target Pharma
By Jill Wechsler
US presidential hopefuls look to comparative effectiveness analysis to address price and access issues
Opinion
Relaunching Reform
By Humphrey Taylor
This time, powerful interest groups (like pharma) that sank the Clinton healthcare bill are on the side of change
Global Report
Tightening the Chain
By Sarah Houlton
EU makes plans to police its supply chain
Thought Leader
The Buddy System
By Jean-Marc Niemetz
Jean-Marc Niemetz on forming partnerships with the industry's major stakeholders
Leadership
Perfectly Imperfect
By Sander Flaum
Everyone makes mistakes; how you handle them is the measure of a true leader
From the Editor
Everybody's Right
By Patrick Clinton
The great debate on DTC advertising is heating up again. We're going to be hearing a lot about fair balance and risk communication and costs. But what about the patients?

ADVERTISEMENT

Click here